Metrics as of 10/16/2026, 11:57 AM (Berlin time), refresh in progress.
enGene Holdings Stock
enGene Holdings Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Canada
- CEO
- Ronald H. W. Cooper
- Employees
- 82
- Market cap
- $115 M
- IPO
- 01/02/2022
Operating through its subsidiary, enGene, Inc., enGene Holdings Inc. functions as a clinical-stage biotechnology firm. Its core mission involves pioneering genetic pharmaceuticals, achieved by administering therapeutic agents directly to mucosal tissues and other bodily organs. A key asset in its pipeline is EG-70,…
enGene Holdings stock: price history
1D
+9.6%
1W
-3.9%
1M
-9.5%
6M
-78.8%
YTD
-81.1%
1Y
-80.6%
2Y
-79.6%
5Y
–
10Y
–
Next earnings date
Next earnings date
22/12/2026 (in 66 days)
Volatility around earnings
~23% weaker price swings than usual
Pattern chart
Pattern detected by the Market Jury detector vdouble-bottom-top-v1.0 on 13/10/26. Not a buy or sell signal.Beta
What does this mean?
Double top
BearishThe price failed at a similar high twice, with a pullback in between. This M-shaped pattern is a classic reversal signal from an uptrend into a downtrend.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
Ask the agents about enGene Holdings
Analyst assessment of enGene Holdings
PRICE TARGET LOW
US$2.00
CONSENSUS
US$3.00
MEDIAN
US$3.00
PRICE TARGET HIGH
US$4.00
0
STRONG BUY
3
BUY
5
HOLD
1
SELL
0
STRONG SELL
9
TOTAL · Hold
As of: 09/09/2026
enGene Holdings stock metrics
P/E
-6.11
P/B
0.52
EV/EBITDA
-0.81
RETURN ON EQUITY
14.1%
NET MARGIN
0.0%
DEBT/EQUITY
0.14
DIVIDEND YIELD
0.0%
AS OF
31/07/2026
Free float & liquidity
FREE FLOAT
36.6%
FLOAT SHARES
24,518,386
AVG. DAILY VOLUME (30D)
761,226
Insider transactions (SEC)
Grossman William
Institutional holders
Dividends
Comparable stocks
Frequently asked questions about enGene Holdings stock
What does enGene Holdings do?
enGene Holdings Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in Canada.
The CEO is Ronald H. W. Cooper, the company employs around 82 people.
The IPO was on 01/02/2022; the stock trades on NASDAQ under the ticker ENGN.
What do analysts say about enGene Holdings stock?
9 analysts rate the stock, the consensus is Hold (as of 09/09/2026).
The average price target is US$3.00, ranging from US$2.00 to US$4.00, with a median of US$3.00.
This is an external assessment, not a statement by Market Jury.
When does enGene Holdings report next?
The next earnings date is 22/12/2026.
Around past earnings, price swings were roughly -23% stronger than usual.
Does enGene Holdings pay a dividend?
Yes. The last dividend was US$0.13 per share.
The dividend yield is 0.0% (as of 31/07/2026).
Which stocks are comparable to enGene Holdings?
Comparable stocks include AbCellera Biologics, Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, argenx, Revolution Medicines, BeOne Medicines and Incyte.
How can I get enGene Holdings stock analyzed?
Clicking "Analyze stock" lets five strategies assess enGene Holdings against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.